Shalekenov B.U., Kuandykov E.A.
THE IMPROVEMENT OF QUALITY OF LIFE USING ULTRA-LOW DOSES OF ANTIBODIES IN THE THERAPY OF BENIGN PROSTATIC HYPERPLASIA
Department of Urology, Andrology and Sexopathology (Head of the Department, Doctor of Medicine, Prof. Shalekenov B.)
Introduction. Benign prostatic hyperplasia (BPH) occurs in elderly men. According to the autopsy data, morphological signs of BPH are registered at the age of 40-50 years in approximately 25% of men, 50-60 years in 50%, 60-70 years in 65%, 70-80 years in 80% and 80-90 years - in 90% [1,2,3]. However, that clinical manifestations of the disease occur only in 25-50% of patients with microscopic or macroscopic signs of BPH, and among them only 50% of patients apply for medical care [4,5].
